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The mechanism of bile acid induced cholestatic liver injury remains controversial, thus hindering the 
development of new therapies for these diseases. In this research highlight, we briefly review the evolution of our 
understanding of the pathogenesis of bile acid induced liver injury, and summarize our recent findings on this 
topic. Our data suggests that under pathophysiological conditions bile acid induced liver injury is mediated by 
inflammatory responses that are initiated from stressed hepatocytes. We conclude by mentioning potential new 
therapeutic approaches for treating cholestatic liver injury based on these pathophysiologic concepts. 
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Chronic cholestasis, whatever the cause, results in liver 
injury where elevated hepatic levels of bile acid contribute to 
the exacerbation of the disease. However, the mechanism 
remains controversial. Earlier concepts held that high hepatic 
levels of bile acids killed hepatocytes through their direct 
cytolytic effects [1-3]. In these studies, cultured human 
hepatocytes were exposed to submillimolar levels of toxic 
secondary bile acids. However, the concentration of these 
bile acid species in patient serum rarely reached these 
experimental levels [4]. Subsequent studies proposed that the 
cause of cell death in cholestasis was due to bile acid induced 
hepatocyte apoptosis [5]. This hypothesis was primarily based 
on observations in cultured rat hepatocytes treated with high 
levels (≥50 µM) of glycodeoxycholic acid or 
glycochenodeoxycholic acid (GCDCA) [6-8]. However 1) 
GCDCA is not a major endogenous bile acid in rodents, and 
its concentrations in serum and liver are less than 10 µM 
 
even in bile duct ligated rats [9]; and 2) no apoptotic cells 
have been detected in cholestatic livers [10-12]. In contrast, 
taurocholic acid (TCA), the major endogenous bile acid in 
rodents, did not cause apoptosis in these cells even at 
millimolar concentrations [7]. Recently, Allen et al showed 
that TCA treatment of cultured mouse hepatocytes (200 µM 
for 6 h) stimulated chemokine expression [13]. These authors 
proposed that bile acid induced liver injury was mediated via 
an acute inflammatory response. This hypothesis is also 
supported by finding neutrophil infiltrations in necrotic areas 
of liver following bile duct ligation in rodents [14]. They also 
found that the bile acid induction of chemokines is FXR 
independent but partially Egr1-dependent [13]. Since Egr1 is a 
transcription factor expressed in many cells and tissues, they 
speculated that bile acid activation of Egr1 was mediated 
through a membrane receptor although the nature of this 
signaling pathway remained elusive [13]. In addition, the 
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functional significance of bile acid induced chemokine 
production in liver injury remained to be explained. 
 
Our interest in the mechanism of bile acid induced liver 
injury came about by observations we obtained concerning 
the evolution and progression of cholestatic liver injury in  
the Mdr2 (Abcb4)-/- mouse [15, 16]. In those studies, we 
sequentially assessed the development of liver injury over 
time in 10-day, 3-week, 6-week and 12-week old Mdr2-/- 
mice by examining liver histology, gene expression, 
neutrophil infiltration, and plasma levels of bile acids at these 
various time points compared to their littermate wild-type 
controls. Plasma levels of bile acids in these Mdr2-/- mice 
were significantly higher than in the wild-type controls at all 
time periods measured after birth and rose in parallel with the 
increased expression in the liver of proinflammatory  
cytokine mRNAs for Tnfα, Ccl2, Cxcl1, and Cxcl2. In 10-
day old mice, the number of hepatic neutrophils were similar 
between Mdr2-/- and wild-type control mice. However, 
marked elevations in neutrophil infiltrations were first 
detected in the 3-week Mdr2-/- livers, while histological 
evidence of liver injury did not become apparent until these 
Mdr2-/- mice were 6-weeks of age. This chronological data 
clearly indicated that a hepatic inflammatory response 
precedes in time the development of liver injury, thus  
directly supporting the concept that it is the cytokine induced 
inflammatory response that first results in cholestatic liver 
injury. 
 
In our recent study, summarized below, we more directly 
assessed the role of proinflammatory chemokines in 
cholestatic liver injury [12]. First, we challenged Ccl2-/- mice 
and their wild-type controls with 1% cholic acid in their diet 
for 7 days. Significantly lower levels of plasma bile acids  
and alanine aminotransferase (ALT) were found in Ccl2-/- 
livers than in the wild-type controls, suggesting that deletion 
of the chemokine Ccl2 protects mice from cholestatic liver 
injury presumably by muting the inflammatory response. To 
confirm these results, we examined the effects of 7-day bile 
duct ligation in these Ccl2-/- mice. Assessment of liver 
histology revealed marked necrosis in the wild-type livers, 
that was nearly absent in Ccl2-/- livers. Plasma ALT in wild-
type mice was 3 times the levels seen in Ccl2-/- mice, despite 
similar levels of plasma bile acids in both genotypes. FACS 
analysis and immunohistochemistry demonstrated 
significantly less infiltrates of neutrophils and T-cells but not 
macrophages in the livers from Ccl2-/- mice when compared 
to the wild-type control. Together, these findings confirmed 
that inflammatory chemokines play a key role in bile acid 
induced liver injury where neutrophils and T-cells may 
mediate these events. 
 
To further investigate the mechanism of this bile acid 
induced inflammatory response in the liver, we first isolated 
liver parenchymal and non-parenchymal cells from the mice 
and treated them with the major species of endogenous bile 
acids for various times. Only hepatocytes were induced to 
stimulate the expression of proinflammatory chemokines 
(Ccl2, Cxcl1 and Cxcl2) while bile acid concentrations of 
TCA (up to 200 µM) had no effect on the non-parenchymal 
cell fraction or on isolated cholangiocytes, whereas all of 
these cells had a cytokine response to LPS treatment. The 
induction of chemokines in hepatocytes was both dose- and 
time-dependent. Even at concentrations as low as 25 µM, 
albeit a pathophysiological relevant concentration, 24 h 
treatment of TCA significantly induced Ccl2 and Cxcl2 
mRNA expression. Similar studies in human hepatocytes 
confirmed these observations. Further functional cell 
migration assays in transwell cultures, demonstrated that 
chemokines released into the culture medium from bile acid 
treated hepatocytes but not non-parenchymal cells were able 
to stimulate neutrophil chemotaxis. These observations 
confirmed that only hepatocytes but not other cells in the 
liver initiate an inflammatory response when exposed to 
pathophysiological relevant levels of bile acids. 
 
To better understand why bile acids stimulated the 
expression of chemokines in hepatocytes but not other liver 
cells, we examined the role of the bile acid uptake transporter, 
Ntcp/Slc10a1. We found that bile acid induction of the 
chemokine Cxcl2 was significantly diminished when Ntcp 
expression was knocked down by siRNAs or when bile acid 
uptake was blocked by a newly synthesized Ntcp inhibitor in 
these cells. These findings indicated that bile acids had to be 
transported into the hepatocyte in order to initiate the 
synthesis of these cytokines. This conclusion is also 
consistent with observations from a rare case of an NTCP-
deficient patient and also in Ntcp(Slc10a1)-/- mice, where 
extremely high levels of bile acids were found in the plasma 
but both the patient and the Ntcp null mice were completely 
protected from cholestatic liver injury [17, 18]. Because 
NTCP/Ntcp is a hepatocyte specific protein in humans and 
rodents, this explains why the other hepatic non-parenchymal 
cells are more resistant to bile acid induced tissue injury. 
These findings also argue against a role for a plasma 
membrane receptor in the hepatocyte in mediating this 
cascade of events [13]. 
 
To further investigate the intracellular events caused by 
bile acid accumulation in hepatocytes and also to better 
elucidate the signaling pathways involved in the induction of 
chemokines, we found that elevated hepatic levels of bile 
acid caused endoplasmic reticulum stress and mitochondria 
damage, evidenced by the organelle specific proteins leaking 
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into cytosol as well as mitochondrial membrane potential 
changes after bile acid treatment, findings consistent with 
previous reports [19, 20]. However, we did not detect ROS in 
these cells and the antioxidants N-Acetyl Cysteine or Mito-Q 
had little effect on repressing bile acid induction of Cxcl2. 
Alternatively, because bile acids caused mitochondrial 
damage, we speculated that toll-like receptor 9 (Tlr9) might 
be activated. As anticipated, bile acid induction of chemokine 
Cxcl2 was significantly diminished in Tlr9-/- mouse 
hepatocytes. Similar results were also obtained in hepatocytes 
from the MyD88/Trif double knock out mouse, two proteins 
that are down-stream signaling molecules of Tlr9. Conversely, 
bile acids and the Tlr9 agonist synergistically stimulated 
Cxcl2 expression in mouse hepatocytes. Most importantly, 
liver injury was also reduced in hepatic specific Tlr9-deficient 
mice although not eliminated. Therefore, we speculate that 
there are likely to be additional signaling pathways involved 
in bile acid induction of chemokine expression in hepatocytes 
and further mechanistic studies will be needed. 
 
Finally, to verify whether our findings from mouse cells 
and cholestatic rodent models described above were 
representative of the pathogenesis of cholestasis in human 
patients, we treated primary human hepatocytes with bile 
acids and also examined liver histology from patients with 
various cholestatic disorders. We found that GCDCA, the 
major endogenous bile acid in humans significantly induced 
chemokine CCL2 CCL15, CCL20, CXCL1 and IL-8 mRNA 
expression after exposure to 50 µM, a pathophysiological 
relevant concentration. We also found that serum ALT levels 
in cholestatic patients, measured around the time of obtaining 
liver tissue, positively correlated with the degree of  periportal 
neutrophil infiltration in these biopsies. These findings are 
consistent with our rodent studies and emphasize the 
importance of the bile acid induced inflammatory response in 
the pathogenesis of cholestatic liver disease in man. 
 
In summary, recent findings from our research and that of 
others indicate that a hepatocyte initiated inflammatory 
response plays a key role in bile acid induced cholestatic liver 
injury. Indeed, these studies point to several new targets for 
treatment of cholestasis since reducing the bile acid pool size, 
blocking bile acid uptake into hepatocytes, minimizing 
mitochondrial injury, and or blocking cytokine production or 
its inflammatory response are all distinct approaches that 
might reduce cholestatic liver injury. These findings 
emphasize that future therapeutic breakthroughs in this field 
may need to explore blocking multiple targets that are 
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